Patents by Inventor Kazuma Tomizuka

Kazuma Tomizuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200236915
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Application
    Filed: September 12, 2019
    Publication date: July 30, 2020
    Inventors: Yoshimi KUROIWA, Kazuma TOMIZUKA, Hitoshi YOSHIDA, Isao ISHIDA
  • Patent number: 10646544
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: May 12, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Makoto Kakitani, Kazuma Tomizuka
  • Patent number: 10448622
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: October 22, 2019
    Assignees: E. R. Squibb & Sons, L.L.C., Kyowa Hakko Kirin Co., Ltd
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 10076103
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 18, 2018
    Assignees: KYOWA HAKKO KIRIN CO., LTD., E.R. SQUIBB & SONS, L.L.C.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Publication number: 20170266255
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 21, 2017
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Makoto KAKITANI, Kazuma TOMIZUKA
  • Patent number: 9700594
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: July 11, 2017
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Makoto Kakitani, Kazuma Tomizuka
  • Publication number: 20170190781
    Abstract: According to the present invention, anti-death receptor 3 (DR3) antagonistic IgG antibodies and antibody fragments thereof, wherein the antibodies and the antibody fragments thereof display a decreased agonistic activity or no agonistic activity for DR3 through their binding, an antibody compositions and an antibody fragment compositions comprising them, a nucleotide sequence encoding the antibody or the antibody fragment, a vector comprising the nucleotide sequences, an amino acid sequences of the antibodies or the antibody fragments, a method of producing the antibodies or the antibody fragments thereof, and a method of decreasing the agonistic potency of an antibody against DR3 through its binding, are provided.
    Type: Application
    Filed: October 8, 2015
    Publication date: July 6, 2017
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: David MILLS, Kazuma TOMIZUKA, John LAUDENSLAGER, Rinpei NIWA, Mami TSUCHIYA
  • Publication number: 20170099814
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Application
    Filed: October 19, 2016
    Publication date: April 13, 2017
    Applicants: E.R. Squibb & Sons, L.L.C., Kyowa Hakko Kirin Co. Ltd.
    Inventors: YOSHIMI KUROIWA, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Patent number: 9499838
    Abstract: The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody ? light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the nonhuman animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: November 22, 2016
    Assignees: KYOWA HAKKO KIRIN CO., LTD., E. R. SQUIBB & SONS, L.L.C.
    Inventors: Yoshimi Kuroiwa, Kazuma Tomizuka, Hitoshi Yoshida, Isao Ishida
  • Publication number: 20160324131
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 10, 2016
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Patent number: 9426970
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: August 30, 2016
    Assignees: E. R. SQUIBB & SONS, L.L.C., KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Patent number: 8951789
    Abstract: This invention relates to a mammalian artificial chromosome vector, which retains a human chromosome 7 fragment comprising human cytochrome P450 genes and is transmittable to progeny, wherein the human chromosome 7 fragment retains a region of approximately 1 MbĀ±500 Kb in size comprising at least a human CYP3A gene cluster, which region is located between chromosome markers AC004922 and AC073842, and to a non-human mammalian animal retaining the vector.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: February 10, 2015
    Assignees: National University Corporation Tottori University, Chromocenter Inc.
    Inventors: Mitsuo Oshimura, Yasuhiro Kazuki, Takashi Matsuoka, Kazuma Tomizuka, Takeshi Oshima
  • Publication number: 20140380515
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 25, 2014
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • Patent number: 8835712
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: September 16, 2014
    Assignees: Medarex, L.L.C., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Patent number: 8809045
    Abstract: This invention relates to a human artificial chromosome (HAC) vector carrying a human chromosome-derived centromere, a subtelomere sequence, and a telomere sequence, to a human cell medicine or human cells comprising the HAC vector, to methods for preparing the HAC vector and human cells, and to methods for producing a therapeutic protein using the HAC vector.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: August 19, 2014
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Minoru Kakeda, Kazuma Tomizuka, Mitsuo Oshimura, Yasuhiro Kazuki
  • Patent number: 8703482
    Abstract: The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein.
    Type: Grant
    Filed: October 7, 2010
    Date of Patent: April 22, 2014
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Mitsuo Oshimura, Motonobu Katoh, Kazuma Tomizuka, Yoshimi Kuroiwa, Minoru Kakeda
  • Publication number: 20130230520
    Abstract: This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
    Type: Application
    Filed: April 24, 2013
    Publication date: September 5, 2013
    Applicant: Kyowa Hakko Kirin Co., Ltd
    Inventors: Makoto KAKITANI, Kazuma TOMIZUKA
  • Publication number: 20120093785
    Abstract: The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein.
    Type: Application
    Filed: October 7, 2010
    Publication date: April 19, 2012
    Inventors: Mitsuo Oshimura, Motonobu Katoh, Kazuma Tomizuka, Yoshimi Kuroiwa, Minoru Kakeda
  • Patent number: 8124406
    Abstract: The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fragment(s) into a cell with high homologous recombination efficiency through its fusion with said microcell; (b) in said cell with high homologous recombination efficiency, inserting a targeting vector by homologous recombination into a desired site of said foreign chromosome(s) or a fragment(s) thereof, and/or a desired site of a chromosome(s) derived from said cell with high homologous recombination efficiency, thereby marking said desired site; and (c) in said cell with high homologous recombination efficiency, causing deletion and/or translocation to occur at the marked site of said foreign chromosome(s) or a fragment(s) thereof.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: February 28, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kazuma Tomizuka, Hitoshi Yoshida, Kazunori Hanaoka, Mitsuo Oshimura, Isao Ishida, Yoshimi Kuroiwa
  • Patent number: 8110671
    Abstract: The specification relates to a method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent cell by fusion with the microcell; a chimeric non-human animal which can be produced by the above method and its progeny; tissues and cells derived therefrom; and a method for using the same. Further, a pluripotent cell containing a foreign chromosome(s) or a fragment(s) thereof, a method for producing the same, and a method for using the same are also provided. Moreover, a pluripotent cell in which at least two endogenous genes are disrupted, and a method for producing the same by homologous recombination are provided.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: February 7, 2012
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kazuma Tomizuka, Hitoshi Yoshida, Kazunori Hanaoka, Mitsuo Oshimura, Isao Ishida